Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

New treatment of early fetal chylothorax

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Timing of Delivery for Twins With Growth Discordance and Growth Restriction: An Individual Participant Data Meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Exposure to Tramadol During Early Pregnancy and Risk of Spontaneous Abortion or Major Congenital Malformations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Human Papillomavirus Testing in the Last Cervical Screening Round at Age 60-64 Years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies at Delivery in Women, Partners, and Newborns

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Unexplained fever in children-Benefits and challenges of FDG-PET/CT

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Risk factors for neonatal sepsis in Sub-Saharan Africa: a systematic review with meta-analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Asthma is associated with pregnancy loss and recurrent pregnancy loss: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: To evaluate OK-432, a preparation of Streptococcus pyogenes, in the treatment of early fetal chylothorax.

METHODS: A prospective study of all fetuses (n=7) with persistent early chylothorax (gestational ages 16-21 weeks) referred to the tertiary center of fetal medicine in Denmark in 2003-2005. Fetuses were injected with 0.2-1.0 mg of OK-432 into the pleural cavity. The treatment was repeated if there were persistent or increasing pleural effusions after 1-3 weeks. The main outcome measures included remission of pleural effusions and fetal and infant morbidity and mortality.

RESULTS: Total remission of pleural effusions was obtained in all fetuses after one or two intrapleural injections of OK-432. No adverse effects of the treatment were observed. No fetus developed hydrops, and all experienced an uncomplicated third trimester. All children were born healthy without pleural effusions, lung hypoplasia, or hydrops.

CONCLUSION: Persistent early chylothorax is a condition with a high mortality rate and no established treatment option. Use of OK-432 is a promising therapy for selected fetuses with persistent chylothorax early in the second trimester.

OriginalsprogEngelsk
TidsskriftObstetrics and Gynecology
Vol/bind109
Udgave nummer5
Sider (fra-til)1088-92
Antal sider5
ISSN0029-7844
DOI
StatusUdgivet - maj 2007

ID: 45032021